Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
2017; Royal Society of Chemistry; Volume: 8; Issue: 11 Linguagem: Inglês
10.1039/c7sc02103h
ISSN2041-6539
AutoresTzu‐Lan Yeh, T.M. Leissing, Martine I. Abboud, Cyrille C. Thinnes, Onur Atasoylu, James P. Holt‐Martyn, Dong Zhang, Anthony Tumber, Kerstin Lippl, Christopher T. Lohans, Ivanhoe K. H. Leung, Helen Morcrette, I.J. Clifton, Timothy D. W. Claridge, Akane Kawamura, Emily Flashman, Xin Lü, Peter J. Ratcliffe, Rasheduzzaman Chowdhury, Christopher W. Pugh, Christopher J. Schofield,
Tópico(s)Metabolism, Diabetes, and Cancer
ResumoFour compounds in clinical trials for anaemia treatment are potent inhibitors of the hypoxia inducible factor (HIF) prolyl hydroxylases (PHDs), but differ in potency and how they interact with HIF at the PHD active site.
Referência(s)